John Ayers believes most healthcare AI hype has not yet translated into meaningful patient impact — though he thinks that may soon change. This belief drove Ayers and a team
In a recent letter, a group of 48 employer and consumer organizations are calling on the Trump Administration to strengthen oversight of certified independent dispute resolution (IDR) entities, which resolve
Despite the availability of many hypertension drugs, many people find these medicines don’t work well enough. A first-in-class AstraZeneca medication now has FDA approval, giving patients a new way to
This month, Cigna announced during its first quarter earnings call that it is exiting its individual exchange business or the Obamacare exchanges at the end of the year, affecting 369,000
Biopharmaceutical companies aim to make taking a biologic drug as simple as possible for patients, marketing many of these chronically administered medicines in self-injection pens for quick and easy dosing.
Every year, seasonal pressures stretch hospital capacity to its limits. Periods of increased admissions often force hospitals to postpone elective surgeries as staff and resources are diverted to more urgent
Today’s healthcare leaders are largely being sold “AI-as-a-service”: SaaS products that solve a specific task and connect to other SaaS products, enhanced with AI, as a wave of startups pushes
For many tertiary care hospitals, not offering extracorporeal membrane oxygenation (ECMO) is increasingly difficult to justify. Choosing not to offer ECMO means patients who could survive are instead transferred, delayed,
An Aardvark Therapeutics clinical trial that has been on voluntary pause for nearly three months due to a safety signal is now formally under an FDA clinical hold, and the
Anomaly Insights, an AI-powered payer intelligence company, announced Wednesday that it raised $17 million in funding. The company’s platform analyzes healthcare transactions to identify payer behavior patterns, policy changes and
